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In this review, we describe the sex differences in prevalence, onset, symptom profiles and disease 
outcome that are evident in schizophrenia, bipolar disorder and post-traumatic stress disorder. 
Women with schizophrenia tend to exhibit less disease impairment than men; by contrast, women 
with post-traumatic stress disorder are more affected than men. The most likely candidates to 
explain these sex differences are the presence of sex hormones. This review details the clinical 
evidence that estradiol and progesterone are dysregulated in these psychiatric disorders. Notably, 
existing data on estradiol, and to a lesser extent, progesterone, suggest that low levels of sex 
hormones may increase the risk of disease development and worsen symptom severity. We argue 
that future studies require a more inclusive, considered analysis of sex hormones and the intricacies 
of the interactions between them, with methodological rigour applied, to enhance our 










BD: bipolar disorder 
CNS: central nervous system 
DHEA: dehydroepiandrosterone 
ER: estrogen receptor 
HPA: hypothalamic-pituitary-adrenal 
HPG: hypothalamic-pituitary-gonadal 
PTSD: post-traumatic stress disorder 
PR: progesterone receptor 
  
1. Introduction  
Sex differences are prevalent in disorders affecting the central nervous system (CNS). 
Schizophrenia, mood disorders including depression and bipolar disorder (BD), post-traumatic 
stress disorder (PTSD), autism and multiple sclerosis are examples of such conditions that report 
sexually dimorphic incidence rates, symptomology or prognosis. While there are a number of 
biological, cultural and environmental factors that may underlie these sex differences, the 
important role of sex steroids has become increasingly evident in recent decades. Sex steroids have 
potent and widespread effects in the brain and the role of ovarian hormones have been of particular 
interest. Accumulating evidence demonstrates the influence of sex hormones on cognition and 
various pathophysiological pathways, in addition to their therapeutic potential. Throughout the 
lifespan, mammalian females experience various endogenous fluctuations in ovarian hormones, 
which can influence the symptom profile of CNS disorders. Such fluctuations include the recurring 
oscillations of estradiol and progesterone across the reproductive cycle (i.e. the menstrual cycle), 
the dramatic changes throughout pregnancy and post-partum that orchestrate reproduction, and the 
overall decline in circulating hormone levels associated with reproductive senescence (i.e. 
menopause). Researchers have utilised these natural variations in estradiol and progesterone to 
investigate their effects on the expression of psychiatric disorders and subsequently glean insight 
into the mechanisms of endogenous sex steroids and how they may act in concert with each other. 
More recently, the impact of exogenous sex steroid administration has been investigated, 
highlighting their therapeutic potential. In this review, therefore, we summarise the literature 
describing sex differences in psychiatric disorders, and then probe whether these differences are 
due to the influence of ovarian hormones. We outline the evidence of sex hormone dyregulation 
in each disorder, emphasising the similarities across disorders. The integral role of estradiol and 
progesterone in psychiatry is highlighted and a number of unanswered questions are posed as 
improvements for further studies are suggested.  
Schizophrenia, BD and PTSD are sexually dimorphic psychiatric disorders that show similarities 
in clinical/cognitive symptomatology, aetiology and neurobiology. In the next section we detail 
evidence of sex differences in these three disorders, focussing on the differences between men and 
women in disease incidence, onset and symptom expression. 
 
2. Sex differences in psychiatric disorders 
2.1 Schizophrenia  
Schizophrenia is a chronic disorder characterised by multiple symptom categories, including 
positive psychotic symptoms, negative symptoms, disordered thought/speech, and cognitive 
deficits (APA, 2013). Sex differences in schizophrenia are widely documented in the literature, 
reportedly affecting several domains including disease onset, course of illness, and symptom 
profiles (Gogos et al., 2015; Ochoa et al., 2012; Sun et al., 2016). The incidence of schizophrenia 
is more prevalent in men (1.4:1 male:female ratio) (McGrath et al., 2004), who typically 
experience peak onset between the ages of 18-25 – approximately 4 years earlier than women 
(Galderisi et al., 2012; Hafner, 2003). Additionally, women uniquely exhibit a second surge of 
disease onset around 45-49 years, suggested to be attributed to the decline of ovarian hormones 
due to menopause (Hafner, 2003; Sun et al., 2016). Sex differences in disease progression and 
prognosis have also been observed, with men showing less responsiveness to antipsychotic 
medication (Szymanski et al., 1995), and longer, more frequent hospitalisations (Szymanski et al., 
1995; Usall et al., 2003). Men also exhibit greater substance abuse (Koster et al., 2008; Ochoa et 
al., 2012), social isolation, and withdrawal than women (Koster et al., 2008; Zhang et al., 2012), 
who have better social prognoses, including retainment of marriages, interpersonal relationships 
(Hafner, 2003; Vila-Rodriguez et al., 2011), and employment (Cotton et al., 2009; Vila-Rodriguez 
et al., 2011). Furthermore, women experience lower rates of remission, and higher rates of 
recovery than men (Carpiniello et al., 2012). Whilst the sex differences in schizophrenia are 
typically observed post-diagnosis, a recent review suggests their presence prior to the onset of 
clinically detectable symptoms, with men displaying poorer premorbid functioning than women, 
including greater social withdrawal, isolation, and poor self-care (Mendrek et al., 2016).  
In addition to the sex differences in social and behavioural domains, men with schizophrenia 
experience more brain morphological abnormalities than women. For example, gross anatomical 
studies show greater ventricular enlargement (Narr et al., 2001), and more severe frontal and 
temporal lobe atrophy in men (Bryant et al., 1999; Narr et al., 2001). Furthermore, men also show 
greater abnormalities in white matter microstructure (Kanaan et al., 2012; Kelly et al., 2018). 
Research regarding sex differences in symptomology in schizophrenia remains less clear. Some 
studies report that women suffer more positive (Thorup et al., 2007) and affective symptoms than 
men (Ochoa et al., 2012; Zhang et al., 2012), and several studies suggest milder symptoms overall 
in women, including fewer cognitive deficits (Han et al., 2012), and less severe negative symptoms 
(Bakhshi et al., 2015; Galderisi et al., 2012; Grossman et al., 2008; Koster et al., 2008). By 
contrast, others failed to identify any sex differences in positive or negative symptoms (Han et al., 
2012; Ochoa et al., 2012; Szymanski et al., 1995). Furthermore, both men (Morgan et al., 2008) 
and women (Szymanski et al., 1995) have been reported as suffering greater depressive symptoms, 
and women experience worse negative symptoms than men (Galderisi et al., 2012). There are 
several possible explanations for these discrepancies, including inconsistent methodology, 
sampling variation and size, and the use of different symptom evaluation tools, particularly when 
comparing earlier versus recent studies. Sex-specific differences in comorbid and psychosocial 
factors including substance abuse (Riecher-Rössler et al., 2018), and access to, or engagement 
with social supports may also explain some of the sex differences observed (Grossman et al., 
2008). These issues highlight the need for further investigation into sex differences using a 
systematic approach to control for confounding variables.  
 
2.2 Bipolar Disorder  
BD is a complex disorder characterised by extreme fluctuations in mood, from manic highs to 
depressive lows (APA, 2013). The lifetime incidence of BD is approximately 1:1 in men and 
women, although the incidence of manic episodes and unipolar mania is higher in men with the 
disease (Diflorio et al., 2010). Research suggests an increased prevalence of BD-II and hypomania 
in women, with general functioning being significantly better for men with this BD subtype 
(Diflorio et al., 2010). Women with BD also report increased rates of rapid cycling in some but 
not all studies (Baldassano et al., 2005; Diflorio et al., 2010; Robb et al., 1998). Reports of sex 
differences in psychosis symptoms are inconsistent; with some studies finding an increased 
prevalence in men versus women (Morgan et al., 2005) or vice-versa (Bräunig et al., 2009), and 
others finding no differences at all (Kessing, 2004). Comorbid phobia, panic disorder, PTSD, 
eating disorders and borderline personality disorder are more frequently reported in women than 
men with BD, while higher rates of comorbid conduct and substance use disorders are reported in 
men (Diflorio et al., 2010; Suominen et al., 2009). 
Most extant studies indicate an equivocal age of onset across the sexes, although some have 
reported that women may be slightly older than men when the disease manifest (Diflorio et al., 
2010; Kawa et al., 2005; Robb et al., 1998; Suppes et al., 2001). Recurrent depressive polarity and 
a depressive or mixed onset has been shown to predominate in women with BD (Kessing, 2004; 
Viguera et al., 2001), while mania may be more prevalent in men at first onset (Kawa et al., 2005; 
Suppes et al., 2001). Owing to inconsistent literature, it is not clear if there are sex differences in 
the number of depressive or manic episodes (Baldassano et al., 2005; Diflorio et al., 2010; Robb 
et al., 1998). However, some studies do show an increased use of antidepressant treatment in 
women with BD, as well as of benzodiazepines, electroconvulsive therapy and psychotherapy 
(Baldassano et al., 2005; Karanti et al., 2015). On the other hand, men appear to be treated with 
lithium more often (Karanti et al., 2015), but sex differences in its clinical response are not evident 
(Viguera et al., 2001). Women with BD have far increased rates of hypothyroidism (when lithium-
treated) and are at increased risk of migraine, compared to men; while rates of metabolic syndrome 
appear to be equivocal across the sexes (Diflorio et al., 2010; Saunders et al., 2014).  
Sex-specific effects on cognitive profiles have been largely unexplored in the BD literature. 
However, there is some evidence to show that men with BD perform worse on visuospatial 
construction (Gogos et al., 2010) and better on spatial memory and sustained attention tasks 
(Bücker et al., 2014) compared to women with BD but not controls. Men with BD have also been 
found to have worse verbal memory performance (Carrus et al., 2010), worse recognition of happy 
prosody (Van Rheenen et al., 2013) and reduced sensorimotor gating (Gogos et al., 2009) 
compared to male controls; while worse recognition of surprise and fear prosody (Bozikas et al., 
2007) and increased sensorimotor gating (Gogos et al., 2009) has been seen in women with BD 
compared to female controls. One study showed that women with BD experience greater cognitive 
benefit from vigorous physical activity than men with BD (Fellendorf et al., 2017).  
In terms of brain morphology, there is no evidence of sex differences in global grey or white 
matter, limbic, or ventricular and sulcal volumes (Jogia et al., 2012). Reduced grey matter volume 
of the medial prefrontal cortex however, has been reported in men with BD compared to male 
controls (Almeida et al., 2009; Jogia et al., 2012). Further, right hippocampal volume loss is 
evident in women versus men with BD (Shi et al., 2018) but not controls. Women with BD also 
exhibit abnormal neural engagement of the caudate and prefrontal cortex during social-cognitive 
tasks compared to female controls (Jogia et al., 2012). Overall, compared to schizophrenia there 
is very little research investigating sex differences in BD. However, the available data show that 
there are sex differences in a number of domains of BD, supporting the idea that sex differences 
are an important consideration in BD.   
 
2.3 Post-Traumatic Stress Disorder 
PTSD is a common disorder that occurs after experiencing a traumatic event involving threat to 
life or physical integrity (APA, 2013). It is characterised by re-experiencing symptoms including 
intrusive memories and nightmares of the trauma, avoidance of trauma reminders, hyper-arousal 
and dysregulation in mood, cognition and in the hypothalamic-pituitary axis (Pitman et al., 2012). 
There are several known risk factors for PTSD, including previous psychiatric or trauma history, 
family psychiatric history, and age at trauma onset. One of the most robust known risk factors of 
PTSD is being female.  Large scale epidemiological and prospective studies consistently report 
that women develop PTSD at approximately twice the rate of men following trauma (Christiansen 
et al., 2015; Kessler et al., 2017; Olff, 2017; Tolin et al., 2006). Longitudinally, the PTSD sex 
difference is highest between the ages of 21 and 25, with men and women reporting their highest 
rates of PTSD in their 40s and 50s, respectively (Ditlevsen et al., 2010). 
Sex differences in the risk of PTSD are not attributable to measurement errors, reporting bias or 
methodological issues (Christiansen et al., 2015; Tolin et al., 2006). A multiplicity of factors 
(social, cognitive, biological and genetic) may contribute to this sex difference; for example, 
women are exposed to greater interpersonal and sexual violence, which lead to greater rates of 
PTSD (Christiansen et al., 2015; Forbes et al., 2014; Kessler et al., 2017; Olff, 2017).  In contrast, 
men are typically exposed to more industrial accidents, war and combat trauma and physical 
assaults (Kessler et al., 2017). This raises the question, if women are associated with more toxic 
forms of trauma exposure such as sexual violence, might this explain their heightened risk of 
developing PTSD? The most definitive test of whether sex differences in PTSD can be attributed 
to sex differences in prevalence of exposure to different types of trauma was in the largest study 
in a US sample of >34,000 participants (Blanco et al., 2018).  Lifetime prevalence for PTSD was 
9.48% in women and 5.97% in men, and women experienced childhood maltreatment and 
assaultive violence more often than men.  However, the difference in prevalence to exposure to 
differing trauma types did not explain the differential risk of PTSD in women and men.  In fact, 
most types of trauma (17 out of 19) were associated with greater risk of PTSD in women than in 
men. A key finding of this study was that a difference in reactivity to trauma, regardless of the 
type of trauma, explained more than 60% of the differential PTSD risk in women and men (Blanco 
et al., 2018).  
In epidemiological studies, there are initial sex differences in reactivity to trauma with increased 
peri-traumatic dissociation and perception of life threat reported as more prevalent immediate 
responses in women than men (Bryant et al., 2003; Irish et al., 2011; Norris et al., 2002; Solomon 
et al., 2005). Differences in symptom presentation appear to dissipate somewhat over time, with 
studies reporting similar symptomology between men and women, albeit women reporting 
stronger intensity across all symptoms (Carragher et al., 2016; Murphy et al., 2018). There are few 
studies reporting sex differences in standard experimental tasks that assess PTSD mechanisms and 
risk factors. In one imaging study, however, increased blood-oxygen-level dependent (BOLD) 
activation was observed in the right amygdala and anterior cingulate cortex of healthy women 
compared to men during a fear conditioning task, a task where reduction in arousal to analogue 
trauma (e.g. electric shock) is measured physiologically (Lebron-Milad et al., 2012). Further, we 
showed that women have greater negative memory consolidation than men in response to stress-
induction, suggesting a potential mechanism for the greater female prevalence for developing 
PTSD (Felmingham et al., 2012c). 
Women appear to be more responsive to PTSD treatment than men, with studies reporting better 
treatment gains and maintenance to exposure and behavioural therapies in female patients 
(Felmingham et al., 2012a; Galovski et al., 2013; Stenmark et al., 2014).  Most recently, a meta-
analysis of 48 of these studies confirmed that women indeed have better treatment responses than 
men, though this was primarily using studies employing behavioural interventions and differences 
in responses to pharmacological treatment were not reported (Wade et al., 2016).  Interestingly, it 
is also reported that women with, but not without, PTSD express higher fear responses to a 
conditioned stimulus than men (Inslicht et al., 2013), which may explain the success during 
exposure therapy, due to the reliance of the technique on effective reactivation of trauma 
memories. However, there has not been sufficient research to identify why treatment responses are 
better in women, with tentative explanations involving increased learning capacity in females 
during both trauma experience and extinction training (Felmingham et al., 2012a).  
3. Are sex hormones the mediating factor?  
The neurobiological complexity of the psychiatric disorders described above contributes to the fact 
that the exact mechanisms underlying the aetiology of these disorders remain elusive. However, 
the most commonly attributed candidate to explain the sex differences described above, is the 
dysfunction of neuroactive sex steroid systems (Gogos et al., 2015; Sun et al., 2016). For example, 
the above observations underpin the estrogen hypothesis of schizophrenia, which postulates a 
protective role of estrogens against the development and severity of the disorder. Similarly, in 
relation to PTSD, evidence of sex differences has led to the hypothesis that low estradiol results in 
poor extinction recall. The reproductive life cycle in women makes them particularly sensitive to 
rapid and/or cyclical variation in levels of sex hormones at different time periods. In this section, 
we briefly describe the two primary ovarian sex hormones and then detail evidence of sex hormone 
dysfunction in each of the psychiatric disorders of interest. 
 
3.1 The main female sex steroid hormones: Estrogens and Progesterone  
The ovarian hormones, estrogens and progesterone, are also neuroactive steroids which play a 
crucial role in glial and neuronal development, structure, and function. Of these, progestogens are 
a class of neuroactive steroids that bind to, and activate progesterone receptors. In humans, 
endogenous progesterone (P4) is the most potent and abundant progestogen subtype. It is 
synthesised both centrally and peripherally via catalysis of pregnenolone, a cholesterol-derived 
steroid precursor (Sun et al., 2016; Tsutsui, 2008) (Figure 1). As a precursor to estrogens, 
testosterone (main male sex hormone), and various glucocorticoids and mineralocorticoids, 
progesterone plays a crucial role in both male and female health and development. In adult males, 
serum progesterone levels reportedly range between 1-3 nM with little change relative to age 
(Oettel et al., 2004; Sun et al., 2016). In contrast, non-pregnant premenopausal women experience 
variable serum progesterone levels relative to their menstrual cycle, with lowest concentrations 
reported during the early follicular phase (0.3-2 nM) and maximum concentrations during the mid-
luteal phase (20-55 nM) (Mumford et al., 2010; Sun et al., 2016). Progesterone levels are highest 
during pregnancy, with serum progesterone steadily increasing throughout the gestational period, 
and reaching peak concentrations of up to 4-fold non-pregnant levels at term (Byrns, 2014; Schock 
et al., 2016). By contrast, serum progesterone levels dramatically decline following menopause 
(Santoro, 2005).  
The term estrogen describes a class of structurally and functionally similar compounds, the most 
common of which are estrone (E1); 17β estradiol, or ‘estradiol’ (E2); and estriol (E3) (Thomas et 
al., 2013). Of these, estradiol is the most potent endogenous estrogen in humans (Gogos et al., 
2015; Jeyakumar et al., 2011), and the focal estrogen of this review. The synthesis of estrogens 
occurs both centrally and peripherally, and is mediated via aromatisation of testosterone (Figure 1). 
Estradiol is present in both males and females, however adult males show considerably lower total 
serum estradiol than females (140 pM) (Sun et al., 2016; Yamamoto et al., 1995), with minimal 
fluctuations or age-related decline (Greenblatt et al., 1976; Orwoll et al., 2006). Conversely, non-
pregnant premenopausal women exhibit biphasic cyclic variation in serum estradiol during their 
28-day menstrual cycle; lowest estradiol levels during the early follicular phase (~75 pM), highest 
levels during the pre-ovulatory phase (~800 pM), and a second, smaller peak during the mid-luteal 
phase (~270 pM) (Schuster et al., 2010; Sun et al., 2016). During pregnancy, estradiol levels 
increase up to 9-fold, but drop dramatically post-partum (Schock et al., 2016). Similarly, estradiol 
levels decline dramatically following menopause, reaching levels ≤100 pM (Burger et al., 1998). 
Sex steroids may work via either organisational or activational effects. Organisational mechanisms 
refer to the effects of sex steroids during prenatal and early postnatal development that result in 
permanent effects on the brain. Whilst activational mechanisms are the receptor-mediated transient 
actions of sex steroids that occur predominantly in adulthood. Throughout the brain, progesterone 
and estradiol function by directly binding to receptors that act via genomic and non-genomic 
mechanisms (Gogos et al., 2015; Newton-Mann et al., 2017; Petersen et al., 2013). Of these, the 
most common of the genomic receptors are ligand-modulated transcription factors known as 
progesterone receptor (PR) PRA and PRB, and estrogen receptor (ER) ERα and ERβ. Following 
the diffusion of the steroid hormone across the cellular membrane, it then activates its cytoplasmic 
receptor, triggering conformational changes that result in receptor homo- or hetero-dimerisation. 
The dimerised receptors then translocate to the nucleus where they bind to promoter regions of 
target genes and regulate transcription (Ellmann et al., 2009). Dimerised ERs specifically bind to 
activator protein 1 sites or estrogen response elements, enabling transcription of estrogen-
responsive genes (Newton-Mann et al., 2017). The non-genomic effects of progesterone are 
primarily mediated via several membrane-bound receptors (mPRs); estrogenic signalling also 
occurs via membrane-bound receptors (mERs), and G protein-coupled estrogen receptor 1 
(GPER). The non-genomic effects of these steroids are rapid and involve activation of a range of 
downstream effects (Newton-Mann et al., 2017; Petersen et al., 2013).   
To summarise, in women, estradiol and progesterone levels fluctuate throughout the reproductive 
lifespan. Further, these levels are much higher in women than in men. Whilst progesterone 
primarily exerts its effects via activating its receptors, it also has significant indirect effects via its 
conversion into a number of neuroactive molecules, including testosterone and estrogens. This 
constant, complex interaction between sex hormones needs to be recognised before one can 
consider the effects of hormones across the reproductive life cycle. 
 
3.2 Evidence of sex hormone dysregulation in Schizophrenia 
Women with schizophrenia often experience symptom fluctuation relative to their menstrual cycle 
phase, and also experience high rates of irregular menses – a common symptom of sex hormone 
dysfunction (Gleeson et al., 2016). Further, the cyclical exacerbation of symptoms corresponds to 
periods of low levels of estradiol and progesterone in the menstrual cycle (Bergemann et al., 2007; 
Hoff et al., 2001; Kumari et al., 2010), during which times women also experience increased rates 
of hospitalisation (Bergemann et al., 2002). Similarly, symptom improvements during pregnancy, 
and worsening of symptoms post-partum correspond to increased and decreased sex hormone 
levels, respectively (Riecher-Rössler, 2017). This is also true for the mid-life surge of female 
diagnoses, which correspond with menopause (Ochoa et al., 2012), with women over the age of 
forty receiving new diagnoses at approximately twice the rate of men (Riecher-Rössler, 2017). 
The above findings may be explained, at least in part, to chronic hypoestrogenism in schizophrenic 
patients. Low serum estradiol has been reported in both male (Belvederi Murri et al., 2016; Doğan 
Bulut et al., 2016) and female (Bergemann et al., 2002; Bergemann et al., 2007) patients with 
schizophrenia and first-episode psychosis  with serum estradiol varying relative to menstrual phase 
in females. Women showed reduced estradiol levels throughout the entire menstrual cycle, with 
hypoestrogenism identified during the follicular phase (defined as serum estradiol below 30 
pg/ml), as well as the peri-ovulatory phase (defined as serum estradiol below 100 pg/ml). It is 
important to note that these effects are thought to be unrelated to antipsychotic drug treatment-
induced hyperprolactinemia, which can itself induce a hypoestrogenic state (McGregor et al., 
2017). Similarly, compared to healthy controls, lower serum progesterone has been reported in 
both male and female patients with schizophrenia (Bicikova et al., 2013; Doğan Bulut et al., 2016; 
Ritsner et al., 2007). Finally, antipsychotic medications were reported to significantly increase 
pregnenolone levels in the brain, suggesting that correction of aberrant progesterone signalling 
may be partially involved in their efficacy (Ritsner, 2011).  
At present, research into the use of hormonal therapies in schizophrenia is providing promising 
results (reviewed in (Gogos et al., 2015; Sbisa et al., 2017)). Studies by Kulkarni and colleagues 
demonstrated that combined antipsychotic and estradiol therapy significantly improved symptoms 
in premenopausal female patients, particularly the positive symptoms, and improved general 
psychopathology in male patients, without causing feminising side-effects (reviewed in (Kulkarni 
et al., 2012)). Similarly, a double-blind placebo-controlled trial found that combined 
administration of haloperidol and a synthetic estradiol significantly improved both positive and 
negative symptoms in premenopausal women with chronic schizophrenia (Akhondzadeh et al., 
2003). Unfortunately, long-term use of estradiol may be associated with side-effects including 
increased cardiovascular and cancer risk (Sbisa et al., 2017). Additionally, the ligand-binding 
domains for ERα and ERβ are highly homologous (Newton-Mann et al., 2017), making it difficult 
to selectively target these receptors using orthosteric ligands. In an attempt to subvert these issues, 
researchers are exploring the therapeutic potential of selective estrogen receptor modulators that 
elicit tissue-dependent agonist, or antagonist effects (Sbisa et al., 2017). As such, reviews have 
concluded that combined antipsychotic and raloxifene therapy improves both positive and negative 
symptoms in women with schizophrenia, and improves negative symptoms in men with 
schizophrenia (Bratek et al., 2016; McGregor et al., 2017). In women with treatment-resistant 
schizophrenia, raloxifene reduced symptom severity and improved likelihood of clinical response 
(Kulkarni et al., 2016). By contrast, another study found that severely ill, postmenopausal women 
with schizophrenia receiving adjunct raloxifene did not show symptom improvement, and in fact 
experienced worsened positive and negative symptoms (Weiser et al., 2017). The authors 
concluded that whilst raloxifene may be beneficial for some patients, further research is needed to 
identify suitable subgroups for safe administration.  
Interestingly, one study found that adjunctive low-dose pregnenolone improved positive 
symptoms, extrapyramidal side effects, and several measures of executive function in chronically 
ill male and female patients (Ritsner, 2010). Furthermore, progesterone administration has been 
shown to improve cognition in healthy women (Berent-Spillson et al., 2015) suggesting it may be 
of benefit for the cognitive deficits in schizophrenia. However, progesterone and its receptors have 
received considerably less attention than estradiol in the neuropsychiatric community, thus further 
research is needed to better understand the role of progesterone, as well as other neuroactive 
compounds, in schizophrenia (Sun et al., 2016). Overall, there is strong evidence for a role of sex 
hormones in schizophrenia and in particular, that reduced estradiol levels may be a predisposing 
factor to disease development and symptom severity in at-risk populations.  
 
3.3 Evidence of sex hormone dysregulation in Bipolar Disorder  
A large proportion of women with BD have menstrual abnormalities that precede diagnosis 
(Rasgon et al., 2005). There are a number of studies providing evidence that reproductive life cycle 
events associated with hormonal fluctuations, specifically a reduction in hormone levels, can 
influence the course of BD. For example, perimenstrual mood changes are reported in 40-65% of 
BD women (Blehar et al., 1998; Teatero et al., 2014), and those women who experience 
perimenstrual mood changes are at higher risk for post-partum relapse (Perich et al., 2017), a worse 
course of illness and increased symptom severity (Dias et al., 2011). Rapid cycling, comorbid 
anxiety and mixed mood episodes, as well as an earlier age of mania or depression onset are also 
more frequently reported in BD women who have reported reproductive life cycle associated mood 
changes (Perich et al., 2017). The luteal phase of the menstrual cycle (both early and late luteal, 
i.e. low hormone levels) has been associated with greater manic/depressive symptoms compared 
to other phases (Rasgon et al., 2003; Shivakumar et al., 2008). An elevation of mood and psychosis 
symptoms post-partum is common (Blehar et al., 1998; Jones et al., 2014), with one study 
reporting an 8-fold increase in the prevalence of mania symptoms in BD women in the week 
following childbirth compared to during pregnancy (Heron et al., 2009). Some clinical studies also 
show high rates of emotional disturbance with an onset in pregnancy, although epidemiological 
studies indicate that the prevalence rate for first time hospitalisations for mood episode during 
pregnancy is low (Jones et al., 2014). The risk of BD relapse during the post-partum period is 
estimated at 35%, with relapse rates higher in women who are medication naïve during pregnancy 
compared to those that aren’t (Wesseloo et al., 2015). Notably, conversion from major depressive 
disorder to BD also appears to be several fold higher in the first six months post-partum than 
typically seen annually (Sharma et al., 2014). Transition to menopause is also commonly 
characterised by an increase in mood disturbance in women with BD (Blehar et al., 1998; Marsh 
et al., 2015). Longitudinal evidence indicates that progression from pre to postmenopausal stages 
is associated with a decrease in mood stability associated with increasing depressive and 
decreasing mania symptoms (Marsh et al., 2012).  
While this clinical evidence implicates fluctuations in sex hormones in the phenomenology of BD 
in women, research on sex hormone profiles in the disorder is sparse. One study reported 
significantly decreased cerebrospinal fluid levels of pregnenolone in BD patients irrespective of 
sex, that was driven by patients who were depressed rather than euthymic at the time of testing 
(George et al., 1994). Another study reported that relative to controls, euthymic BD women had 
increased circulating progesterone and allopregnanolone (active metabolite of progesterone) but 
not cortisol concentrations during the luteal phase of the menstrual cycle (Hardoy et al., 2006). In 
contrast, two other studies found that the progesterone and estradiol levels of women with BD 
(either rapid cycling or with post-partum BD relapse) did not differ from control women during 
either mid-luteal or follicular phases of the menstrual cycle (Karadag et al., 2004; Wieck et al., 
2003). Finally, testosterone levels were lower in depressed men with BD, but higher in depressed 
women with BD, compared to their respective control counterparts (Wooderson et al., 2015). 
Higher testosterone levels during a depressive or mixed episode have been associated with an 
increased incidence of mania and suicide attempts in BD patients irrespective of sex (Sher et al., 
2012), with baseline testosterone predictive of future suicidal behaviour in depressed or mixed 
episode BD women (Sher et al., 2014).  
Further evidence for the involvement of sex hormones in BD comes from studies where women 
were receiving exogenous estrogenic treatments. A small study reported that there were no 
significant mood changes in women with BD who were taking oral contraceptives (containing 
combined synthetic estradiol and progesterone) on the active versus inactive (placebo) days, but 
there was a slight but significant worsening of mood in BD women not taking oral contraceptives 
(first seven days of cycle versus last seven days) (Rasgon et al., 2003). Several small clinical trials 
also highlight the efficacy of the synthetic progesterone, medroxyprogesterone, and a selective 
estrogen receptor modulator, tamoxifen, for the treatment of acute mania (Kulkarni et al., 2014; 
Meinhard et al., 2014). In a study of women with post-partum psychosis and estrogen deficiency, 
psychosis symptoms were ameliorated with daily estradiol treatment (Ahokas et al., 2000). 
Pregnenolone has also been shown to be efficacious for the treatment of BD depression, although 
the mechanism of action is unclear given that changes in depressive symptoms did not correlate 
with changes in serum pregnenolone or other neurosteroids (Brown et al., 2014). The evidence for 
sex hormone dysregulation in women with BD is supported by studies showing a worsening of 
symptoms during times of low levels of sex hormones, and by clinical trials suggesting that certain 
sex hormones can improve specific symptoms of BD.  
 
3.4 Evidence of sex hormone dysregulation in Post-Traumatic Stress Disorder 
Sex hormones are thought to be a critical factor in the contrasting rates of PTSD diagnoses between 
men and women (Ney et al., 2018; Rasmusson et al., 2017). Human studies have identified 
estradiol as an important regulator of the recall of extinction memories (Glover et al., 2015), which 
is the quintessential process underlying recovery from a traumatic experience. This may be 
expected, given the known importance of estradiol on memory, learning and cognitive processes 
more generally (Frick et al., 2015; Gogos et al., 2014; Sbisa et al., 2017). In studies of fear 
extinction in healthy women, it has been found that higher estradiol levels are associated with 
improved task performance, where participants learn that a previously aversive stimulus is no 
longer associated with an aversive experience (for example, an electric shock) with success gauged 
by change in physiological arousal upon presentation of the stimulus (Graham et al., 2013; Milad 
et al., 2010; Wegerer et al., 2014; Zeidan et al., 2011). Similar studies have found that women 
with higher levels of endogenous estradiol more successfully extinguish fear memories compared 
to women using hormonal contraceptives (Graham et al., 2013; Li et al., 2016; White et al., 2016).  
The effect of menstrual cycle phase on fear extinction in healthy women is less consistent, with a 
large scale study finding no significant differences between phases (Lonsdorf et al., 2015).   
Although no study has examined long-term estradiol levels in PTSD patients, there has been some 
research measuring sex hormones in PTSD. One study found that women with PTSD and low 
estradiol levels had intensified physiological responding to an aversive laboratory stimulus than 
non-PTSD women with low estradiol levels, with estradiol measured in saliva.  This effect was 
absent in women with high estradiol levels, where PTSD and non-PTSD participants displayed 
similar responding to the aversive stimulus, strongly suggesting a protective effect of estradiol on 
fear learning (Glover et al., 2012). Women with PTSD were also shown to exhibit increased phobic 
anxiety and depression during the early follicular compared to mid-luteal phase of the menstrual 
cycle (Nillni et al., 2015). In another study, women with PTSD in the mid-luteal phase of the 
menstrual cycle exhibited impaired fear extinction compared to women in the early follicular phase 
(Pineles et al., 2016), which is the reverse finding of healthy participants. Whilst it is unclear what 
the mechanistic implications of these findings might be, recent genetic studies have identified 
estradiol-related risk factors for PTSD, with estrogen-response elements on the pituitary adenylate 
cyclase-activating peptide (PACAP) receptor gene, PAC1R, associated with PTSD severity in 
women but not men (Lind et al., 2017).  This is a significant finding since PACAP deficiency is 
associated with impaired production of transcriptional factors underlying both the HPA and 
sympathetic stress responses in mice {Stroth, 2010 #1534}. The recent meta-analysis by Lind and 
colleagues (2017) therefore provides evidence of sex hormone influences on stress reactivity at the 
genetic level, and a possible diverging factor in prevalence and severity of PTSD between the 
sexes.  Further, the DNA methylation of estradiol on the HDAC4 gene may be associated with fear 
learning and memory (Maddox et al., 2018).   
Whereas estrogenic signalling is implicated in effective recovery following a traumatic experience, 
consolidation of emotional memories may instead be associated with progesterone levels at the 
time of trauma. Studies of real-world trauma have shown that increased reports of flashback 
memories and increased PTSD symptomology are associated with hospitalisation during the mid-
luteal phase (Bryant et al., 2011), which is characterised by peak progesterone levels as well as 
elevated estradiol.  Similarly, survivors of sexual assault who neglected to take emergency 
contraception (which contains high dose progesterone) were significantly more likely to report 
higher PTSD symptomology compared to those who did take emergency contraception (Ferree et 
al., 2012).  In the laboratory, healthy women who are in the mid-luteal phase report more intrusive 
memories of negative stimuli (Ertman et al., 2011; Wassell et al., 2015), and this effect is 
correlated with levels of progesterone but not estradiol at encoding (Ertman et al., 2011; 
Felmingham et al., 2012b; Wassell et al., 2015).  Only one study has found that estradiol was 
associated with increased reports of intrusive memories (Cheung et al., 2013); conversely another 
study found that estradiol was associated with decreased reports of intrusions (Wegerer et al., 
2014). Overall, a number of studies support a facilitative effect of progesterone levels on intrusive 
memories of emotionally negative stimuli during encoding, with inconsistent or negligible effects 
of estradiol. 
  
4. Future directions and implications  
The exact mechanisms underlying the sex differences in the severe psychiatric disorders described 
above are unclear, but likely involve genetic factors, biological, cognitive and social influences. 
In this review, we have focussed on the role of sex hormones, particularly the main female 
neuroactive steroids, estradiol and progesterone, to explain the sex differences. Whilst it is 
common for researchers to investigate the role of sex hormones in women, what about men? 
Estradiol and progesterone may also play an important role on symptom severity in men (Kulkarni 
et al., 2013), conversely it may be that testosterone is the key hormone influencing disease 
development and severity in men. This is an important issue and yet an understudied area; again 
highlighting that future research should always consider both males and females.  
Based on the evidence presented here, it is clear that female sex hormone variation informs similar 
symptom profiles across schizophrenia, BD, and PTSD. In both schizophrenia and BD, low levels 
of estradiol are associated with increased manic and psychotic-like symptoms, as demonstrated in 
both experimental and observational studies (Gogos et al., 2015; Meinhard et al., 2014).  In PTSD, 
low estradiol levels are associated with poorer recovery following a traumatic experience and 
continuity of PTSD symptoms (Glover et al., 2015), while progesterone levels may influence the 
consolidation of emotional memories at the time of trauma.  In all of these disorders, higher 
estradiol is generally associated with improved symptomology; this is most relevant to the 
cognitive domain and represents a significant novel treatment avenue (Glover et al., 2015; Gogos 
et al., 2015; Meinhard et al., 2014).  
An intriguing contradiction between symptom profiles of these three disorders is that, despite high 
estradiol recognised as a key protective factor explaining lower rates of schizophrenia and BD-II 
in women, low estradiol is conversely believed to drive higher prevalence of PTSD in women. 
Given that women have higher estradiol levels than men, were estradiol a primary aetiological 
protective factor in all three disorders it might have been expected that women would have lower, 
rather than higher, rates of PTSD as is observed in schizophrenia. This phenomenon is likely 
explainable by the differential influence of hormone fluctuation during different stages of PTSD. 
In PTSD, trauma causes an extreme biological stress response resulting in downregulation of the 
hypothalamic-pituitary-gonadal (HPG) axis and lower production of estradiol and progesterone 
that results in impaired extinction learning long-term (Ney et al., 2018; Toufexis et al., 2014).  
Restoration of these hormones in PTSD, and similarly upregulation in schizophrenia and BD, 
therefore appears to be a promising treatment option for similar reasons between the disorders, 
including through augmentation of cognition. However, high levels of hormones may similarly be 
a risk factor for PTSD through facilitation of learning, which acts to enhance consolidation of 
trauma memories at the time of trauma. The differential effect of hormones in this case reflects 
PTSD as a delayed disorder, characterised by an initial stressor and a later onset of symptomology 
(APA, 2013). 
It is important to recognise that steroid hormones show dynamic interactions, meaning that 
treatment target options may include more than just estradiol. For example, in PTSD, 
downregulation of the HPG axis coincides with interruption of cortisol production in the 
hypothalamic-pituitary-adrenal (HPA) axis following extreme stress created during trauma (Ney 
et al., 2018; Pitman et al., 2012; Toufexis et al., 2014).  Restoration of either of these pathways 
can improve PTSD symptomology through the cognitive aspects of fear extinction learning 
(Glover et al., 2015; Ney et al., 2018; Pitman et al., 2012). It is necessary to consider that these 
axes, as with all steroid hormone production, are inseparable and are dual effectors in disorders 
that are stress-related; not only in PTSD, but cortisol production is chronically dysregulated in 
both schizophrenia and BD (Girshkin et al., 2014). Similarly, the effects of estradiol and 
progesterone in each of these disorders might be better explained by the increasingly recognised 
influence of neuroactive steroids in psychiatric disorders, such as pregnenolone, allopregnanolone, 
testosterone and dehydroepiandrosterone (DHEA) (Rasmusson et al., 2017; Ritsner, 2011; Sun et 
al., 2016). For instance, research has highlighted the importance of allopregnanolone and DHEA 
for fear extinction learning and PTSD symptomology (Rasmusson et al., 2017). A recent study 
showed that men with psychotic features of schizophrenia, BD or major depression had elevated 
DHEA levels compared to those without a history of psychosis (Buoli et al., 2016). Given the 
known interactions between neuroactive steroid hormones, it is important to identify the 
underlying imbalances in hormone levels for each disorder.  For example, in women, PTSD was 
associated with lower levels of 5α-dihydroprogesterone, the primary metabolite of progesterone 
and precursor of allopregnanolone (Pineles et al., 2018), suggesting that pharmacological targeting 
of 5α-dihydroprogesterone, rather than allopregnanolone or progesterone, may be beneficial. 
Findings of an imbalance of various neuroactive steroids in these psychiatric disorders underscores 
the importance of further research into steroid interactions instead of isolated targets such as 
estradiol. 
Overall, this review provides compelling evidence for cross-disorder estradiol-related protective 
mechanisms, which may be expected given the known importance of both genomic and non-
genomic effects of estrogens on cognitive processes more generally (Frick et al., 2015). However, 
estradiol and progesterone have a broad functional diversity in the brain, with both types of 
receptor implicated in multiple processes such as neurogenesis, microglia expression, 
inflammation, and bioenergetics (Gogos et al., 2015; Rettberg et al., 2014; Sun et al., 2016). Given 
this diversity, it is unlikely that sex hormones play a single role in the pathogenesis and 
pathophysiology of PTSD, schizophrenia or BD – rather, their role is likely to regulate various 
signalling, neurodevelopmental, neuroplastic, and epigenetic processes.  As an example, all three 
disorders are characterised by reductions in hippocampal volume and functioning (Lieberman et 
al., 2018; Pitman et al., 2012; Shi et al., 2018), which is attributable to various neurobiological 
mechanisms associated with learning and memory.  Estradiol has been shown to modulate 
phosphorylation of ERK, mTOR and PKA pathways (Fortress et al., 2013; Hasegawa et al., 2015; 
Kim et al., 2016) and can increase dendritic spine density of hippocampal neurons (Luine et al., 
2013).  Phosphorylation of these pathways in turn mediate estrogenic genomic actions including 
DNA methylation and histone acetylation in the hippocampus, subsequently affecting levels of 
proteins such as brain-derived neurotrophic factor (Zhao et al., 2010), which is a potent effector 
of learning and memory and recognised as a critical factor in psychiatric disorders (Luine et al., 
2013; Pitman et al., 2012; Wu et al., 2013). Given the well-established role of neurotransmitter 
dysfunction in psychiatric disorders, it is important to note that both estradiol and progesterone 
modulate the activity of dopaminergic, serotonergic, glutamatergic and GABAergic systems 
(Barth et al., 2015; Gogos et al., 2015; Sun et al., 2016). Neurobiological pathways involved in 
the pathophysiology of these disorders, specifically the prefrontal and limbic networks and their 
connectivity, have also been shown to have sex specificity (Felmingham et al., 2010). Estradiol 
receptors are expressed throughout the hippocampus (Österlund et al., 2000), as well as the 
dorsolateral prefrontal cortex (Montague et al., 2008), for which cross-talk is involved in 
increasing psychotic symptomology (Lieberman et al., 2018) as well as being critical to fear 
circuitry (Pitman et al., 2012). Based on this converging evidence, it is likely that the similarities 
in symptomology between these three disorders is attributed to dysfunction across similar 
estrogenic-mediated mechanisms. In support, the most recent clinical studies have detected large 
genome-wide association overlaps in heritability of vulnerability towards PTSD and 
schizophrenia, with a moderate shared effect between these disorders and BD (Duncan et al., 
2018). Future research will need to assess the extent to which similar mechanisms mediate 
symptomology across disorders and lessons may be learnt by combining methodologies and 
theoretical models between fields. 
Finally, there are some common limitations across studies. Examining the specific effects of sex 
hormones in a naturalistic human setting is particularly difficult. Inconsistencies in the literature 
are likely due to varied methodologies in the population selection (e.g. women in different 
reproductive life stages), and the symptom/task/hormone measures (e.g. estimated cycle phase 
compared to blood levels or saliva assays). To compound this, the lack of methodological detail 
makes it very difficult to compare across studies. For example, when one discusses differences 
across the menstrual cycle, it is often unclear what the effects observed are actually due to – is it 
really a change in estradiol level? Or is it the accompanying increase in progesterone (Sun et al., 
2016) or testosterone levels that are the mediating factors? Further, given the increasing prevalence 
of hormonal contraceptive use by women, studies need to report on contraceptive use, including 
type of contraception, duration of use, and so on.  This is particularly important given the known 
influence of contraceptives, containing synthetic estrogen and progestin, on cognition (Gogos et 
al., 2014). Using animal models of psychiatric disorders is one way we can control for many of 
the confounding variables (Gogos et al., 2015; Sbisa et al., 2017). Future studies require a more 
inclusive, considered effort of sex hormones and the intricacies of the interactions between them, 




Psychiatric disorders such as schizophrenia, BD and PTSD are chronic and debilitating diseases 
that have no cure. Current medications are inadequate; they do not treat all patients of all 
symptoms, nor are they side-effect free. Thus, the need for the development of better treatments, 
or perhaps adjunctive treatments, is clearly important. Could sex hormones, such as estradiol, 
provide the framework for the development of future therapeutics? In this review, three different 
psychiatric disorders were examined, however, there are a number of similarities between them, 
such as cognitive impairment, genetic predisposition, neurotransmitter dysfunction, inflammation, 
and so on. It has been proposed that a mechanism uniting the genetic and neurobiological factors 
implicated in psychiatric disorders might be endocrine responses, specifically estradiol (Blanco et 
al., 2018), which has been described as the ‘master regulator’ (Rettberg et al., 2014). Given the 
fact that the steroid receptors are wide-spread throughout the CNS, and that sex hormones have 
wide-ranging effects on CNS systems, it is not surprising that estradiol and progesterone can 
modulate the expression of psychiatric disorders. Although, whether the influence of sex steroids 
requires organisational or activational effects or genomic or non-genomic actions is not clear, but 
likely involves a combination of these. One thing is obvious, there are marked sex differences 
across multiple disorders; women with schizophrenia tend to exhibit less disease impairment than 
men, but women with PTSD are more affected than men. We implore to researchers and clinicians 
to, at the very least, acknowledge that sex differences exist. Thus future studies should be balanced 
for sex, and in the clinic, women may need to be classified according to their hormone status before 
starting treatment. Illuminating the extent to which sex hormones facilitate these purported sex 
differences, and the associated mechanisms, may lead to avenues for novel therapeutic approaches, 
and allow for precision medicine for men as well as women. This has important potential 
therapeutic implications for the preponderance of neuropsychiatric diseases with sexually 






We gratefully acknowledge the financial support of the National Health and Medical Research 
Council of Australia (AG CDF ID1108098; TVR ECF ID1088785; KLF program grant 
APP1073041). The Florey Institute of Neuroscience and Mental Health acknowledges the support 
from the Victorian Government’s Operational Infrastructure Support Grant. TVR has received 
funding from the Helen McPherson Smith Trust, Swinburne University of Technology, University 
of Melbourne, Society of Mental Health Research, Rebecca L. Cooper Foundation, Jack Brockhoff 








Ahokas A, Aito M, Rimón R (2000). Positive treatment effect of estradiol in postpartum psychosis: 
a pilot study. The Journal of clinical psychiatry 61(3): 166-169. 
 
Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, et al. (2003). 
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, 
and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 27(6): 1007-1012. 
 
Almeida JR, Akkal D, Hassel S, Travis MJ, Banihashemi L, Kerr N, et al. (2009). Reduced gray 
matter volume in ventral prefrontal cortex but not amygdala in bipolar disorder: significant effects 
of gender and trait anxiety. Psychiatry Research: Neuroimaging 171(1): 54-68. 
 
APA (2013). Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. edn. American 
Psychiatric Association: Washington D.C., USA. 
 
Bakhshi K, Chance SA (2015). The neuropathology of schizophrenia: A selective review of past 
studies and emerging themes in brain structure and cytoarchitecture. Neuroscience 303: 82-102. 
 
Baldassano CF, Marangell LB, Gyulai L, Nassir Ghaemi S, Joffe H, Kim DR, et al. (2005). Gender 
differences in bipolar disorder: retrospective data from the first 500 STEP‐BD participants. Bipolar 
Disorders 7(5): 465-470. 
 
Barth C, Villringer A, Sacher J (2015). Sex hormones affect neurotransmitters and shape the adult 
female brain during hormonal transition periods. Frontiers in Neuroscience 9: 37. 
 
Belvederi Murri M, Fanelli F, Pagotto U, Bonora E, Triolo F, Chiri L, et al. (2016). Neuroactive 
Steroids in First-Episode Psychosis: A Role for Progesterone? Schizophrenia research and 
treatment 2016: 1942828. 
 
Berent-Spillson A, Briceno E, Pinsky A, Simmen A, Persad CC, Zubieta JK, et al. (2015). Distinct 
cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology 
59: 25-36. 
 
Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt C, et al. (2002). Acute 
psychiatric admission and menstrual cycle phase in women with schizophrenia. Archives of 
women's mental health 5(3): 119-126. 
 
Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C (2007). Estrogen, menstrual cycle 
phases, and psychopathology in women suffering from schizophrenia. Psychol Med 37(10): 1427-
1436. 
 
Bicikova M, Hill M, Ripova D, Mohr P, Hampl R (2013). Determination of steroid metabolome 
as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol 133: 77-
83. 
 
Blanco C, Hoertel N, Wall MM, Franco S, Peyre H, Neria Y, et al. (2018). Toward Understanding 
Sex Differences in the Prevalence of Posttraumatic Stress Disorder: Results From the National 
Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 79(2). 
 
Blehar MC, DePaulo Jr JR, Gershon ES, Reich T (1998). Women with bipolar disorder: findings 
from the NIMH Genetics Initiative sample. Psychopharmacology Bulletin 34(3): 239. 
 
Bozikas VP, Kosmidis MH, Tonia T, Andreou C, Focas K, Karavatos A (2007). Impaired 
Perception of Affective Prosody in Remitted Patients With Bipolar Disorder. Journal of 
Neuropsychiatry and Clinical Neurosciences 19(4): 436-440. 
 
Bratek A, Krysta K, Drzyzga K, Baranska J, Kucia K (2016). The role of selective estrogen 
receptor modulators in the treatment of schizophrenia. Psychiatria Danubina 28(Suppl-1): 45-48. 
 
Bräunig P, Sarkar R, Effenberger S, Schoofs N, Krüger S (2009). Gender differences in psychotic 
bipolar mania. Gender medicine 6(2): 356-361. 
 
Brown ES, Park J, Marx CE, Hynan LS, Gardner C, Davila D, et al. (2014). A randomized, double-
blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology 
39(12): 2867. 
 
Bryant NL, Buchanan RW, Vladar K, Breier A, Rothman M (1999). Gender differences in 
temporal lobe structures of patients with schizophrenia: a volumetric MRI study. Am J Psychiatry 
156(4): 603-609. 
 
Bryant RA, Felmingham KL, Silove D, Creamer M, O'Donnell M, McFarlane AC (2011). The 
association between menstrual cycle and traumatic memories. J Affect Disord 131(1-3): 398-401. 
 
Bryant RA, Harvey AG (2003). Gender differences in the relationship between acute stress 
disorder and posttraumatic stress disorder following motor vehicle accidents. The Australian and 
New Zealand journal of psychiatry 37(2): 226-229. 
 
Bücker J, Popuri S, Muralidharan K, Kozicky J-M, Baitz HA, Honer WG, et al. (2014). Sex 
differences in cognitive functioning in patients with bipolar disorder who recently recovered from 
a first episode of mania: data from the Systematic Treatment Optimization Program for Early 
Mania (STOP-EM). Journal of Affective Disorders 155: 162-168. 
 
Buoli M, Caldiroli A, Serati M, Grassi S, Altamura AC (2016). Sex Steroids and Major Psychoses: 
Which Role for DHEA-S and Progesterone. Neuropsychobiology 73(3): 178-183. 
 
Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, Green A, et al. (1998). Serum 
inhibins A and B fall differentially as FSH rises in perimenopausal women. Clinical endocrinology 
48(6): 809-813. 
 
Byrns MC (2014). Regulation of progesterone signaling during pregnancy: Implications for the 
use of progestins for the prevention of preterm birth. The Journal of Steroid Biochemistry and 
Molecular Biology 139: 173-181. 
 
Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F (2012). Gender differences in remission 
and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective 
cohort study. Schizophrenia research and treatment 2012: 576369. 
 
Carragher N, Sunderland M, Batterham PJ, Calear AL, Elhai JD, Chapman C, et al. (2016). 
Discriminant validity and gender differences in DSM-5 posttraumatic stress disorder symptoms. 
Journal of Affective Disorders 190: 56-67. 
 
Carrus D, Christodoulou T, Hadjulis M, Haldane M, Galea A, Koukopoulos A, et al. (2010). 
Gender differences in immediate memory in bipolar disorder. Psychological Medicine 40(8): 
1349-1355. 
 
Cheung J, Chervonsky L, Felmingham KL, Bryant RA (2013). The role of estrogen in intrusive 
memories. Neurobiol Learn Mem 106: 87-94. 
 
Christiansen DM, Hansen M (2015). Accounting for sex differences in PTSD: A multi-variable 
mediation model. Eur J Psychotraumatol 6: 26068. 
 
Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD, et al. (2009). 
Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated 
epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 114(1-3): 17-
24. 
 
Dias RS, Lafer B, Russo C, Del Debbio A, Nierenberg AA, Sachs GS, et al. (2011). Longitudinal 
Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-
BD. American Journal of Psychiatry 168(4): 386-394. 
 
Diflorio A, Jones I (2010). Is sex important? Gender differences in bipolar disorder. International 
Review of Psychiatry 22(5): 437-452. 
 
Ditlevsen DN, Elklit A (2010). The combined effect of gender and age on post traumatic stress 
disorder: do men and women show differences in the lifespan distribution of the disorder? Annals 
of General Psychiatry 9: 32-32. 
 
Doğan Bulut S, Bulut S, Güriz O (2016). The relationship between sex hormone profiles and 
symptoms of schizophrenia in men. Comprehensive psychiatry 69: 186-192. 
 
Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-Koch AE, et al. 
(2018). Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex 
differences in heritability. Mol Psychiatry 23(3): 666-673. 
 
Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL (2009). Estrogen and 
progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 66(15): 
2405-2426. 
 
Ertman N, Andreano JM, Cahill L (2011). Progesterone at encoding predicts subsequent emotional 
memory. Learn Mem 18(12): 759-763. 
 
Fellendorf FT, Kainzbauer N, Platzer M, Dalkner N, Bengesser SA, Birner A, et al. (2017). Gender 
differences in the association between physical activity and cognitive function in individuals with 
bipolar disorder. Journal of Affective Disorders 221: 232-237. 
 
Felmingham K, Williams LM, Kemp AH, Liddell B, Falconer E, Peduto A, et al. (2010). Neural 
responses to masked fear faces: sex differences and trauma exposure in posttraumatic stress 
disorder. J Abnorm Psychol 119(1): 241-247. 
 
Felmingham KL, Bryant RA (2012a). Gender differences in the maintenance of response to 
cognitive behavior therapy for posttraumatic stress disorder. J Consult Clin Psychol 80(2): 196-
200. 
 
Felmingham KL, Fong WC, Bryant RA (2012b). The impact of progesterone on memory 
consolidation of threatening images in women. Psychoneuroendocrinology 37(11): 1896-1900. 
 
Felmingham KL, Tran TP, Fong WC, Bryant RA (2012c). Sex differences in emotional memory 
consolidation: the effect of stress-induced salivary alpha-amylase and cortisol. Biol Psychol 89(3): 
539-544. 
 
Ferree NK, Wheeler M, Cahill L (2012). The influence of emergency contraception on post-
traumatic stress symptoms following sexual assault. J Forensic Nurs 8(3): 122-130. 
 
Forbes D, Lockwood E, Phelps A, Wade D, Creamer M, Bryant RA, et al. (2014). Trauma at the 
Hands of Another: Distinguishing PTSD Patterns Following Intimate and Nonintimate 
Interpersonal and Noninterpersonal Trauma in a Nationally Representative Sample. Journal of 
Clinical Psychiatry 75(2): 147-153. 
 
Fortress AM, Fan L, Orr PT, Zhao Z, Frick KM (2013). Estradiol-induced object recognition 
memory consolidation is dependent on activation of mTOR signaling in the dorsal hippocampus. 
Learn Mem 20(3): 147-155. 
 
Frick KM, Kim J, Tuscher JJ, Fortress AM (2015). Sex steroid hormones matter for learning and 
memory: estrogenic regulation of hippocampal function in male and female rodents. Learn Mem 
22(9): 472-493. 
 
Galderisi S, Bucci P, Ucok A, Peuskens J (2012). No gender differences in social outcome in 
patients suffering from schizophrenia. Eur Psychiatry 27(6): 406-408. 
 
Galovski TE, Blain LM, Chappuis C, Fletcher T (2013). Sex differences in recovery from PTSD 
in male and female interpersonal assault survivors. Behaviour research and therapy 51(6): 247-
255. 
 
George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM (1994). CSF neuroactive 
steroids in affective disorders: Pregnenolone, progesterone, and DBI. Biological Psychiatry 
35(10): 775-780. 
 
Girshkin L, Matheson SL, Shepherd AM, Green MJ (2014). Morning cortisol levels in 
schizophrenia and bipolar disorder: a meta-analysis. Psychoneuroendocrinology 49: 187-206. 
 
Gleeson PC, Worsley R, Gavrilidis E, Nathoo S, Ng E, Lee S, et al. (2016). Menstrual cycle 
characteristics in women with persistent schizophrenia. The Australian and New Zealand journal 
of psychiatry 50(5): 481-487. 
 
Glover EM, Jovanovic T, Mercer KB, Kerley K, Bradley B, Ressler KJ, et al. (2012). Estrogen 
levels are associated with extinction deficits in women with posttraumatic stress disorder. Biol 
Psychiatry 72(1): 19-24. 
 
Glover EM, Jovanovic T, Norrholm SD (2015). Estrogen and extinction of fear memories: 
implications for posttraumatic stress disorder treatment. Biol Psychiatry 78(3): 178-185. 
 
Gogos A, Joshua N, Rossell SL (2010). Use of the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) to investigate group and gender differences in schizophrenia 
and bipolar disorder. Australian and New Zealand Journal of Psychiatry 44: 220-229. 
 
Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B (2015). A Role for Estrogen in 
Schizophrenia: Clinical and Preclinical Findings. Int J Endocrinol 2015: 615356. 
 
Gogos A, van den Buuse M, Rossell S (2009). Gender differences in prepulse inhibition (PPI) in 
bipolar disorder: Men have reduced PPI, women have increased PPI. International Journal of 
Neuropsychopharmacology 12(9): 1249-1259. 
 
Gogos A, Wu YC, Williams AS, Byrne LK (2014). The effects of ethinylestradiol and progestins 
("the pill") on cognitive function in pre-menopausal women. Neurochem Res 39(12): 2288-2300. 
 
Graham BM, Milad MR (2013). Blockade of estrogen by hormonal contraceptives impairs fear 
extinction in female rats and women. Biol Psychiatry 73(4): 371-378. 
 
Greenblatt RB, Oettinger M, Bohler Clorinda SS (1976). Estrogen-Androgen Levels in Aging Men 
and Women: Therapeutic Considerations*. Journal of the American Geriatrics Society 24(4): 173-
178. 
 
Grossman LS, Harrow M, Rosen C, Faull R, Strauss GP (2008). Sex Differences in Schizophrenia 
and Other Psychotic Disorders: A 20-Year Longitudinal Study of Psychosis and Recovery. 
Comprehensive psychiatry 49(6): 523-529. 
 
Hafner H (2003). Gender differences in schizophrenia. Psychoneuroendocrinology 28 Suppl 2: 
17-54. 
 
Hammond R, Mauk R, Ninaci D, Nelson D, Gibbs RB (2009). Chronic treatment with estrogen 
receptor agonists restores acquisition of a spatial learning task in young ovariectomized rats. 
Hormones and behavior 56(3): 309-314. 
 
Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, et al. (2012). Gender differences in cognitive 
function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 
39(2): 358-363. 
 
Hardoy MC, Serra M, Carta MG, Contu P, Pisu MG, Biggio G (2006). Increased neuroactive 
steroid concentrations in women with bipolar disorder or major depressive disorder. Journal of 
Clinical Psychopharmacology 26(4): 379-384. 
 
Hasegawa Y, Hojo Y, Kojima H, Ikeda M, Hotta K, Sato R, et al. (2015). Estradiol rapidly 
modulates synaptic plasticity of hippocampal neurons: Involvement of kinase networks. Brain Res 
1621: 147-161. 
 
Heron J, Haque S, Oyebode F, Craddock N, Jones I (2009). A longitudinal study of hypomania 
and depression symptoms in pregnancy and the postpartum period. Bipolar Disorders 11(4): 410-
417. 
 
Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, et al. (2001). 
Association of estrogen levels with neuropsychological performance in women with 
schizophrenia. Am J Psychiatry 158(7): 1134-1139. 
 
Inslicht SS, Metzler TJ, Garcia NM, Pineles SL, Milad MR, Orr SP, et al. (2013). Sex differences 
in fear conditioning in posttraumatic stress disorder. J Psychiatr Res 47(1): 64-71. 
 
Irish LA, Fischer B, Fallon W, Spoonster E, Sledjeski EM, Delahanty DL (2011). Gender 
Differences in PTSD Symptoms: An Exploration of Peritraumatic Mechanisms. Journal of anxiety 
disorders 25(2): 209-216. 
 
Jeyakumar M, Carlson KE, Gunther JR, Katzenellenbogen JA (2011). Exploration of dimensions 
of estrogen potency: parsing ligand binding and coactivator binding affinities. J Biol Chem 
286(15): 12971-12982. 
 
Jogia J, Dima D, Frangou S (2012). Sex differences in bipolar disorder: a review of neuroimaging 
findings and new evidence. Bipolar Disorders 14(4): 461-471. 
 
Jones I, Chandra PS, Dazzan P, Howard LM (2014). Bipolar disorder, affective psychosis, and 
schizophrenia in pregnancy and the post-partum period. The Lancet 384(9956): 1789-1799. 
 
Kanaan RA, Allin M, Picchioni M, Barker GJ, Daly E, Shergill SS, et al. (2012). Gender 
differences in white matter microstructure. PLoS One 7(6): e38272. 
 
Karadag F, Akdeniz F, Erten E, Pirildar S, Yucel B, Polat A, et al. (2004). Menstrually related 
symptom changes in women with treatment‐responsive bipolar disorder. Bipolar Disorders 6(3): 
253-259. 
 
Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, et al. (2015). Gender 
differences in the treatment of patients with bipolar disorder: A study of 7354 patients. Journal of 
Affective Disorders 174: 303-309. 
 
Kawa I, Carter Janet D, Joyce Peter R, Doughty Caroline J, Frampton Chris M, Elisabeth Wells J, 
et al. (2005). Gender differences in bipolar disorder: age of onset, course, comorbidity, and 
symptom presentation. Bipolar Disorders 7(2): 119-125. 
 
Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, et al. (2018). Widespread white 
matter microstructural differences in schizophrenia across 4322 individuals: results from the 
ENIGMA Schizophrenia DTI Working Group. Mol Psychiatry 23(5): 1261-1269. 
 
Kessing LV (2004). Gender differences in the phenomenology of bipolar disorder. Bipolar 
Disorders 6(5): 421-425. 
 
Kessler RC, Aguilar-Gaxiola S, Alonso J, Benjet C, Bromet EJ, Cardoso G, et al. (2017). Trauma 
and PTSD in the WHO World Mental Health Surveys. European Journal of Psychotraumatology 
8. 
 
Kim J, Szinte JS, Boulware MI, Frick KM (2016). 17beta-Estradiol and Agonism of G-protein-
Coupled Estrogen Receptor Enhance Hippocampal Memory via Different Cell-Signaling 
Mechanisms. J Neurosci 36(11): 3309-3321. 
 
Koster A, Lajer M, Lindhardt A, Rosenbaum B (2008). Gender differences in first episode 
psychosis. Soc Psychiatry Psychiatr Epidemiol 43(12): 940-946. 
 
Kulkarni J, Berk M, Wang W, Mu L, Scarr E, Van Rheenen TE, et al. (2014). A Four Week 
Randomized Control Trial of Medroxyprogesterone, and Tamoxifen in Women with Mania 
Psychoneuroendocrinology 43: 52-61. 
 
Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, et al. (2016). Effect of 
Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A 
Randomized Clinical Trial. JAMA Psychiatry 73(9): 947-954. 
 
Kulkarni J, Gavrilidis E, Worsley R, Hayes E (2012). Role of estrogen treatment in the 
management of schizophrenia. CNS drugs 26(7): 549-557. 
 
Kulkarni J, Gavrilidis E, Worsley R, Van Rheenen T, Hayes E (2013). The Role of Estrogen in the 
Treatment of Men with Schizophrenia. International Journal of Endocrinology and Metabolism 
11(3): 129-136. 
 
Kumari V, Konstantinou J, Papadopoulos A, Aasen I, Poon L, Halari R, et al. (2010). Evidence 
for a role of progesterone in menstrual cycle-related variability in prepulse inhibition in healthy 
young women. Neuropsychopharmacology 35(4): 929-937. 
 
Lebron-Milad K, Abbs B, Milad MR, Linnman C, Rougemount-Bucking A, Zeidan MA, et al. 
(2012). Sex differences in the neurobiology of fear conditioning and extinction: a preliminary 
fMRI study of shared sex differences with stress-arousal circuitry. Biol Mood Anxiety Disord 2: 7. 
 
Li S, Graham BM (2016). Estradiol is associated with altered cognitive and physiological 
responses during fear conditioning and extinction in healthy and spider phobic women. Behav 
Neurosci 130(6): 614-623. 
 
Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, et al. (2018). 
Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and 
hypothesis for early detection and intervention. Mol Psychiatry. 
 
Lind MJ, Marraccini ME, Sheerin CM, Bountress K, Bacanu SA, Amstadter AB, et al. (2017). 
Association of Posttraumatic Stress Disorder With rs2267735 in the ADCYAP1R1 Gene: A Meta-
Analysis. J Trauma Stress 30(4): 389-398. 
 
Lonsdorf TB, Haaker J, Schumann D, Sommer T, Bayer J, Brassen S, et al. (2015). Sex differences 
in conditioned stimulus discrimination during context-dependent fear learning and its retrieval in 
humans: the role of  biological sex, contraceptives and menstrual cycle phases. Journal of 
Psychiatry and Neuroscience 40(6): 368-375. 
 
Luine V, Frankfurt M (2013). Interactions between estradiol, BDNF and dendritic spines in 
promoting memory. Neuroscience 239: 34-45. 
 
Maddox SA, Kilaru V, Shin J, Jovanovic T, Almli LM, Dias BG, et al. (2018). Estrogen-dependent 
association of HDAC4 with fear in female mice and women with PTSD. Mol Psychiatry 23(3): 
658-665. 
 
Marsh WK, Gershenson B, Rothschild AJ (2015). Symptom severity of bipolar disorder during 
the menopausal transition. International Journal of Bipolar Disorders 3(1): 17. 
 
Marsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll‐Desrosiers AR, Rothschild AJ (2012). 
Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar 
Disorders 14(5): 515-526. 
 
McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D (2004). A systematic review 
of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, 
migrant status and methodology. BMC Med 2: 13. 
 
McGregor C, Riordan A, Thornton J (2017). Estrogens and the cognitive symptoms of 
schizophrenia: Possible neuroprotective mechanisms. Front Neuroendocrinol 47: 19-33. 
 
Meinhard N, Kessing LV, Vinberg M (2014). The role of estrogen in bipolar disorder, a review. 
Nord J Psychiatry 68(2): 81-87. 
 
Mendrek A, Mancini-Marie A (2016). Sex/gender differences in the brain and cognition in 
schizophrenia. Neurosci Biobehav Rev 67: 57-78. 
 
Milad MR, Zeidan MA, Contero A, Pitman RK, Klibanski A, Rauch SL, et al. (2010). The 
influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience 
168(3): 652-658. 
 
Montague D, Weickert CS, Tomaskovic-Crook E, Rothmond DA, Kleinman JE, Rubinow DR 
(2008). Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. 
J Neuroendocrinol 20(7): 893-903. 
 
Morgan VA, Castle DJ, Jablensky AV (2008). Do women express and experience psychosis 
differently from men? Epidemiological evidence from the Australian National Study of Low 
Prevalence (Psychotic) Disorders. The Australian and New Zealand journal of psychiatry 42(1): 
74-82. 
 
Morgan VA, Mitchell PB, Jablensky AV (2005). The epidemiology of bipolar disorder: 
sociodemographic, disability and service utilization data from the Australian National Study of 
Low Prevalence (Psychotic) Disorders. Bipolar Disorders 7(4): 326-337. 
 
Mumford SL, Schisterman EF, Siega-Riz AM, Browne RW, Gaskins AJ, Trevisan M, et al. (2010). 
A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones 
during the menstrual cycle: findings from the BioCycle study. J Clin Endocrinol Metab 95(9): 
E80-85. 
 
Murphy S, Elklit A, Chen YY, Ghazali SR, Shevlin M (2018). Sex differences in PTSD symptoms: 
A differential item functioning approach. Psychological trauma : theory, research, practice and 
policy. 
 
Narr KL, Thompson PM, Sharma T, Moussai J, Blanton R, Anvar B, et al. (2001). Three-
dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender 
effects. Biol Psychiatry 50(2): 84-97. 
 
Newton-Mann E, Finney C, Purves-Tyson T, Gogos A (2017). Estrogen Receptors: Mechanism 
of Action and Relevance to Schizophrenia. Curr Psychiatry Rev 13(1): 55-64. 
 
Ney LJ, Matthews A, Bruno R, Felmingam KL (2018). Modulation of the endocannabinoid system 
by sex hormones: Implications for Posttraumatic Stress Disorder. Neurosci Biobehav Rev. 
 
Nillni YI, Pineles SL, Patton SC, Rouse MH, Sawyer AT, Rasmusson AM (2015). Menstrual cycle 
effects on psychological symptoms in women with PTSD. J Trauma Stress 28(1): 1-7. 
 
Norris FH, Foster JD, Weisshaar DL (2002). The epidemiology of sex differences in PTSD across 
developmental, societal, and research contexts. edn. 
 
Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J (2012). Gender differences in schizophrenia and 
first-episode psychosis: a comprehensive literature review. Schizophrenia research and treatment 
2012: 916198. 
 
Oettel M, Mukhopadhyay AK (2004). Progesterone: the forgotten hormone in men? The aging 
male : the official journal of the International Society for the Study of the Aging Male 7(3): 236-
257. 
 
Olff M (2017). Sex and gender differences in post-traumatic stress disorder: an update. European 
Journal of Psychotraumatology 8. 
 
Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. (2006). 
Testosterone and Estradiol among Older Men. The Journal of Clinical Endocrinology & 
Metabolism 91(4): 1336-1344. 
 
Österlund MK, Gustafsson J-Ak, Keller E, Hurd YL (2000). Estrogen Receptor β (ERβ) 
Messenger Ribonucleic Acid (mRNA) Expression within the Human Forebrain: Distinct 
Distribution Pattern to ERα mRNA1. The Journal of Clinical Endocrinology & Metabolism 
85(10): 3840-3846. 
 
Perich TA, Roberts G, Frankland A, Sinbandhit C, Meade T, Austin M-P, et al. (2017). Clinical 
characteristics of women with reproductive cycle–associated bipolar disorder symptoms. 
Australian and New Zealand Journal of Psychiatry 51(2): 161-167. 
 
Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J, Lopez JA (2013). 
Novel progesterone receptors: neural localization and possible functions. Frontiers in 
Neuroscience 7: 164. 
 
Pineles SL, Nillni YI, King MW, Patton SC, Bauer MR, Mostoufi SM, et al. (2016). Extinction 
retention and the menstrual cycle: Different associations for women with posttraumatic stress 
disorder. J Abnorm Psychol 125(3): 349-355. 
 
Pineles SL, Nillni YI, Pinna G, Irvine J, Webb A, Arditte Hall KA, et al. (2018). PTSD in women 
is associated with a block in conversion of progesterone to the GABAergic neurosteroids 
allopregnanolone and pregnanolone measured in plasma. Psychoneuroendocrinology 93: 133-141. 
 
Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, et al. (2012). 
Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 13(11): 769-787. 
 
Rasgon N, Bauer M, Glenn T, Elman S, Whybrow Peter C (2003). Menstrual cycle related mood 
changes in women with bipolar disorder. Bipolar Disorders 5(1): 48-52. 
 
Rasgon NL, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, et al. (2005). Reproductive 
function and risk for PCOS in women treated for bipolar disorder. Bipolar Disorders 7(3): 246-
259. 
 
Rasmusson AM, Marx CE, Pineles SL, Locci A, Scioli-Salter ER, Nillni YI, et al. (2017). 
Neuroactive steroids and PTSD treatment. Neurosci Lett 649: 156-163. 
 
Rettberg JR, Yao J, Brinton RD (2014). Estrogen: a master regulator of bioenergetic systems in 
the brain and body. Front Neuroendocrinol 35(1): 8-30. 
 
Riecher-Rössler A (2017). Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and 
schizophrenic psychoses. The Lancet Psychiatry 4(1): 63-72. 
 
Riecher-Rössler A, Butler S, Kulkarni J (2018). Sex and gender differences in schizophrenic 
psychoses—a critical review. Archives of women's mental health. 
 
Ritsner M, Maayan R, Gibel A, Weizman A (2007). Differences in blood pregnenolone and 
dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur 
Neuropsychopharmacol 17(5): 358-365. 
 
Ritsner MS (2011). The clinical and therapeutic potentials of dehydroepiandrosterone and 
pregnenolone in schizophrenia. Neuroscience 191: 91-100. 
 
Ritsner MS (2010). Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and 
clinical trials. CNS Neurosci Ther 16(1): 32-44. 
 
Robb JC, Young LT, Cooke RG, Joffe RT (1998). Gender differences in patients with bipolar 
disorder influence outcome in the medical outcomes survey (SF-20) subscale scores. Journal of 
Affective Disorders 49: 189-193. 
 
Santoro N (2005). The menopausal transition. The American Journal of Medicine 118(12): 1405. 
 
Saunders EF, Nazir R, Kamali M, Ryan KA, Evans S, Langenecker S, et al. (2014). Gender 
differences, clinical correlates and longitudinal outcome of bipolar disorder with co-morbid 
migraine. The Journal of clinical psychiatry 75(5): 512. 
 
Sbisa AM, van den Buuse M, Gogos A (2017). The effect of estradiol and its analogues on 
cognition in preclinical and clinical research: relevance to schizophrenia. In: Gargiulo PA, 
Mesones-Arroyo HL (ed)^(eds). Psychiatry and Neuroscience Update: Bridging the Divide., edn, 
Vol. 2: Springer. p^pp. 
 
Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HA, Idahl A, et al. (2016). 
Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC 
pregnancy and childbirth 16(1): 146. 
 
Schuster J, Karlsson T, Karlström P-O, Poromaa IS, Dahl N (2010). Down-regulation of 
progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells 
associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS). 
Reproductive Biology and Endocrinology : RB&E 8: 58-58. 
 
Sharma V, Xie B, Campbell MK, Penava D, Hampson E, Mazmanian D, et al. (2014). A 
prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in 
pregnancy and postpartum. Bipolar Disorders 16(1): 16-21. 
 
Sher L, Grunebaum MF, Sullivan GM, Burke AK, Cooper TB, Mann JJ, et al. (2014). Association 
of testosterone levels and future suicide attempts in females with bipolar disorder. Journal of 
Affective Disorders 166: 98-102. 
 
Sher L, Grunebaum MF, Sullivan GM, Burke AK, Cooper TB, Mann JJ, et al. (2012). Testosterone 
levels in suicide attempters with bipolar disorder. Journal of Psychiatric Research 46(10): 1267-
1271. 
 
Shi J, Guo H, Fan F, Fan H, An H, Wang Z, et al. (2018). Sex differences of hippocampal structure 
in bipolar disorder. Psychiatry Research: Neuroimaging 273: 35-41. 
 
Shivakumar G, Bernstein IH, Suppes T, Network aTSFB (2008). Are Bipolar Mood Symptoms 
Affected by the Phase of the Menstrual Cycle? Journal of Women's Health 17(3): 473-478. 
 
Solomon Z, Gelkopf M, Bleich A (2005). Is terror gender-blind? Gender differences in reaction to 
terror events. Soc Psychiatry Psychiatr Epidemiol 40(12): 947-954. 
 
Stenmark H, Guzey IC, Elbert T, Holen A (2014). Gender and offender status predicting treatment 
success in refugees and asylum seekers with PTSD. European Journal of Psychotraumatology 5: 
10.3402/ejpt.v3405.20803. 
 
Sun J, Walker AJ, Dean B, van den Buuse M, Gogos A (2016). Progesterone: The neglected 
hormone in schizophrenia? A focus on progesterone-dopamine interactions. 
Psychoneuroendocrinology 74: 126-140. 
 
Suominen K, Mantere O, Valtonen H, Arvilommi P, Leppämäki S, Isometsä E (2009). Gender 
differences in bipolar disorder type I and II. Acta Psychiatrica Scandinavica 120(6): 464-473. 
 
Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. (2001). The 
Stanley Foundation Bipolar Treatment Outcome Network: II. demographics and illness 
characteristics of the first 261 patients. Journal of Affective Disorders 67(1): 45-59. 
 
Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. (1995). Gender 
differences in onset of illness, treatment response, course, and biologic indexes in first-episode 
schizophrenic patients. Am J Psychiatry 152(5): 698-703. 
 
Teatero ML, Mazmanian D, Sharma V (2014). Effects of the menstrual cycle on bipolar disorder. 
Bipolar Disorders 16(1): 22-36. 
 
Thomas MP, Potter BV (2013). The structural biology of oestrogen metabolism. J Steroid Biochem 
Mol Biol 137: 27-49. 
 
Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. (2007). 
Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline 
in the Danish OPUS study. J Nerv Ment Dis 195(5): 396-405. 
 
Tolin DF, Foa EB (2006). Sex differences in trauma and posttraumatic stress disorder: a 
quantitative review of 25 years of research. Psychol Bull 132(6): 959-992. 
 
Toufexis D, Rivarola MA, Lara H, Viau V (2014). Stress and the reproductive axis. J 
Neuroendocrinol 26(9): 573-586. 
 
Tsutsui K (2008). Progesterone biosynthesis and action in the developing neuron. Endocrinology 
149(6): 2757-2761. 
 
Usall J, Ochoa S, Araya S, Marquez M, Group N (2003). Gender differences and outcome in 
schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 18(6): 282-
284. 
 
Van Rheenen TE, Rossell SL (2013). Auditory-prosodic processing in bipolar disorder; from 
sensory perception to emotion. Journal of Affective Disorders 151(3): 1102-1107. 
 
Viguera AC, Baldessarini RJ, Tondo L (2001). Response to lithium maintenance treatment in 
bipolar disorders: comparison of women and men. Bipolar Disorders 3(5): 245-252. 
 
Vila-Rodriguez F, Ochoa S, Autonell J, Usall J, Haro JM (2011). Complex interaction between 
symptoms, social factors, and gender in social functioning in a community-dwelling sample of 
schizophrenia. The Psychiatric quarterly 82(4): 261-274. 
 
Wade D, Varker T, Kartal D, Hetrick S, O'Donnell M, Forbes D (2016). Gender difference in 
outcomes following trauma-focused interventions for posttraumatic stress disorder: Systematic 
review and meta-analysis. Psychological trauma : theory, research, practice and policy 8(3): 356-
364. 
 
Wassell J, Rogers S, Felmingham KL, Pearson J, Bryant RA (2015). Progesterone and mental 
imagery interactively predict emotional memories. Psychoneuroendocrinology 51: 1-10. 
 
Wegerer M, Kerschbaum H, Blechert J, Wilhelm FH (2014). Low levels of estradiol are associated 
with elevated conditioned responding during fear extinction and with intrusive memories in daily 
life. Neurobiology of Learning and Memory 116: 145-154. 
 
Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, et al. (2017). Raloxifene Plus 
Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated 
Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized 
Controlled Trial. J Clin Psychiatry 78(7): e758-e765. 
 
Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V (2015). Risk of 
postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-
analysis. American Journal of Psychiatry 173(2): 117-127. 
 
White EC, Graham BM (2016). Estradiol levels in women predict skin conductance response but 
not valence and expectancy ratings in conditioned fear extinction. Neurobiol Learn Mem 134 Pt 
B: 339-348. 
 
Wieck A, Davies R, Hirst A, Brown N, Papadopoulos A, Marks M, et al. (2003). Menstrual cycle 
effects on hypothalamic dopamine receptor function in women with a history of puerperal bipolar 
disorder. Journal of Psychopharmacology 17(2): 204-209. 
 
Wooderson SC, Gallagher P, Watson S, Young AH (2015). An exploration of testosterone levels 
in patients with bipolar disorder. BJPsych Open 1(2): 136-138. 
 
Wu YC, Hill RA, Gogos A, van den Buuse M (2013). Sex differences and the role of estrogen in 
animal models of schizophrenia: interaction with BDNF. Neuroscience 239: 67-83. 
 
Yamamoto M, Hibi H, Katsuno S, Miyake K (1995). Serum Estradoiol Levels in Normal Men and 
Men With Idiopathic Infertility. International Journal of Urology 2(1): 44-46. 
 
Zeidan MA, Igoe SA, Linnman C, Vitalo A, Levine JB, Klibanski A, et al. (2011). Estradiol 
modulates medial prefrontal cortex and amygdala activity during fear extinction in women and 
female rats. Biol Psychiatry 70(10): 920-927. 
 
Zhang XY, Chen DC, Xiu MH, Yang FD, Haile CN, Kosten TA, et al. (2012). Gender differences 
in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J 
Clin Psychiatry 73(7): 1025-1033. 
 
Zhao Z, Fan L, Frick KM (2010). Epigenetic alterations regulate estradiol-induced enhancement 
of memory consolidation. Proc Natl Acad Sci U S A 107(12): 5605-5610. 
 
 
 
